KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Assets (2016 - 2025)

Ionis Pharmaceuticals has reported Other Non-Current Assets over the past 17 years, most recently at $171.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $171.6 million for Q4 2025, up 34.83% from a year ago — trailing twelve months through Dec 2025 was $171.6 million (up 34.83% YoY), and the annual figure for FY2025 was $171.6 million, up 34.83%.
  • Other Non-Current Assets for Q4 2025 was $171.6 million at Ionis Pharmaceuticals, up from $166.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for IONS hit a ceiling of $171.6 million in Q4 2025 and a floor of $49.0 million in Q3 2021.
  • Median Other Non-Current Assets over the past 5 years was $95.1 million (2023), compared with a mean of $96.0 million.
  • Biggest five-year swings in Other Non-Current Assets: increased 6.72% in 2022 and later surged 75.12% in 2023.
  • Ionis Pharmaceuticals' Other Non-Current Assets stood at $70.6 million in 2021, then grew by 6.72% to $75.3 million in 2022, then soared by 39.73% to $105.3 million in 2023, then rose by 20.89% to $127.3 million in 2024, then skyrocketed by 34.83% to $171.6 million in 2025.
  • The last three reported values for Other Non-Current Assets were $171.6 million (Q4 2025), $166.0 million (Q3 2025), and $132.1 million (Q2 2025) per Business Quant data.